Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash from Financing Activities (2022 - 2025)

Bioregenx's Cash from Financing Activities history spans 4 years, with the latest figure at -$44143.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$44143.0 for Q4 2025, down 535.7% from a year ago — trailing twelve months through Dec 2025 was $33098.0 (down 92.51% YoY), and the annual figure for FY2025 was $33098.0, down 92.51%.
  • Cash from Financing Activities for Q4 2025 was -$44143.0 at Bioregenx, down from $70833.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $513370.0 in Q4 2023 to a low of -$44143.0 in Q4 2025.
  • The 4-year median for Cash from Financing Activities is $46442.0 (2024), against an average of $114700.6.
  • The sharpest move saw Cash from Financing Activities skyrocketed 14571.91% in 2023, then tumbled 535.7% in 2025.
  • Year by year, Cash from Financing Activities stood at $3499.0 in 2022, then skyrocketed by 14571.91% to $513370.0 in 2023, then plummeted by 101.35% to -$6944.0 in 2024, then tumbled by 535.7% to -$44143.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$44143.0, $70833.0, and $16823.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.